Veerhealth Care FY26 Revenue Jumps 86% to ₹33.29 Crore
Veerhealth Care Limited reported a significant 86.08% year-over-year growth in total revenues for FY26, reaching ₹33.29 Crore. EBITDA also saw a substantial increase of 82.68% YoY to ₹3.27 Crore. The company's net profit grew by 38.46% YoY to ₹0.54 Crore. The Q4 FY26 profit was impacted by a Forex Loss of ₹0.31 Crore and a ₹0.49 Crore provision for Deferred Tax, which are not expected to recur in FY27. The company highlighted the positive impact of the India-EU Trade Deal 2026 on Ayurveda exports and is working on scaling manufacturing for medical devices in the U.S. market, with ongoing discussions for oral care exports to Russia. Key milestones include significant orders from the USA, domestic markets, and leading FMCG companies, along with onboarding Ayuveer products on Myntra and commencing production at a new facility with in-house molding. Veerhealth Care also secured USFDA plant clearance, positioning it uniquely among small-cap companies. The company projects revenues of ₹70-75 Crores in FY27 and aims for ₹100 Crores within 24 months.
Key Highlights
- FY26 total revenue surged 86.08% YoY to ₹33.29 Crore.
- EBITDA grew 82.68% YoY to ₹3.27 Crore; Net Profit up 38.46% YoY to ₹0.54 Crore.
- Company secured USFDA plant clearance, a rare achievement for small-caps.
- Projects FY27 revenue of ₹70-75 Crore, targeting ₹100 Crore in 24 months.
- Expansion into U.S. medical devices and Russian oral care markets planned.
Price Impact
More from VEERHEALTH